This extensive suite of services combines Cellca’s cell line and upstream process development expertise with BioOutsource’s bioanalytical and biosafety contract testing expertise to support customers from cell line development, through product manufacture and release. Broadening Sartorius Stedim Biotech’s portfolio of products, technologies and services and enabling a comprehensive “Total Solution” to support our clients’ drug development activities.
Benefit from the combined experience of Cellca, BioOutsource and Sartorius Stedim Biotech to efficiently advance your drug candidates quickly from early stage development through to commercialisation.
Based on its unparalleled global experience working to support biological drug development, BioOutsource and Cellca lead the way in preclinical development. Through our robust platforms, off-the-shelf assays and commitment to providing a total solution, Sartorius Stedim Biotech can accelerate your drug’s development.
BioOutsource and Cellca have industry leading expertise in supporting biosimilar drug development. Collectively we have worked with over 50 biosimilar developers across 12 countries, totalling 230 biosimilar projects. Benefit from our combined experience and integrated services to further mitigate risks and select optimal biosimilar clones. Find out more.
Our service offering is underpinned by our commitment to delivering excellent customer service, navigating our customers through the complexities of the drug development cycle and enabling them to make informed data- driven decisions. Our client management team provide an intimate customer experience and ensure your project is managed efficiently and delivered on time. Effective communication is key to success, and our team understand that a transparent, proactive approach to customer service will ensure the delivery of a truly differentiated solution.